Press Release

Ebrantil became the first α1-blocker approved for neurogenic dysuria in the worldNovember 25, 1999

 KAKEN PHARMACEUTICAL CO., LTD. (president: Shiro Inui) announced that its specific α1 -adrenergic receptor antagonist, the brand name Urapidil, have obtained an approval by the M.H.W. for this new indication in November, 1999. The clinical studies have shown that twice daily administration of Ebrantil capsule significantly improves difficulty of urination by central or peripheral neural disorders without causing significant hypotention. Ebrantil that the company licensed from Byk Gluden has already been in use for treating hypertension and dysuria due to prostatic hypertrophy in Japan since 1989 and 1995, respectively.

 

Back to list